Michael Blaeker

Statistics

Publications

Citations

392

H-Index

Active since

2009

Affiliations

Roche (United Kingdom)(Current)

Imelda Hospital

Michael Blaeker is an author at Roche (United Kingdom) specializing in inflammatory bowel disease therapy, ulcerative colitis pharmacotherapy, and crohn disease pharmacotherapy.

ORCID

Publications per year

2009–2021

Publications

Impaired gastric acidification negatively affects calcium homeostasis and bone mass

Thorsten Schinke, Arndt F. Schilling, Anke Baranowsky et al. · Nature Medicine · 2009 · 206 citations

Medicine, Endocrinology, Physiology +16

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

Silvio Danese, Jean‐Frédéric Colombel, Milan Lukáš et al. · The Lancet. Gastroenterology & hepatology · 2021 · 93 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +14

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Laurent Peyrin‐Biroulet, Ailsa Hart, Peter Bossuyt et al. · The Lancet. Gastroenterology & hepatology · 2021 · 93 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

1–3 of 3